NewGenIvf Group Limited announced that its planned UAE-based operating entity for commercializing its advanced cell-sorting and cytometry platform has received a midpoint equity value of $19 million from a Big Four accounting firm. This valuation follows an independent valuation of the company's advanced cytometry intellectual property at $17.9 million in October 2025. The planned entity will commercialize the platform across the UAE and Gulf Cooperation Council markets by leasing advanced cytometry devices to local clinics and establishing a centralized high-throughput cell-sorting hub in the UAE, targeting reproductive-health and IVF-related applications. The company also appointed Nadeem Malik as Senior Strategic Advisor to lead the commercialization and expansion, citing his previous roles as CEO at Genetics and IVF Institute and President at Fairfax Cryobank. The UAE IVF market is projected to grow from $270 million in 2024 to $444 million in 2030, a compound annual growth rate of 8.5%, according to TechSci Research. Shares of NewGenIvf closed Monday's regular session up 7.78% at $1.49 but were trading down 6.04% at $1.40 in the overnight market.
NewGenIvf Group Limited Class A Ordinary SharesPlanned UAE entity to commercialize advanced cell-sorting platform, with independent IP valuation and market growth projections.